Titre du document / Document title

Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder

Auteur(s) / Author(s)

SURI Rita A. ⁽¹⁾ ; ALTSHULER Lori L. ^{(1 2)} ; RASGON Natasha L. ⁽¹⁾ ; CALCAGNO Jeffrey L. ^{(1 2)} ; FRYE Mark A. ^{(1 2)} ; GITLIN Michael J. ⁽¹⁾ ; SUN HWANG ^{(1 2)} ; ZUCKERBROW-MILLER Joni ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, Calif., ETATS-UNIS
⁽²⁾ Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles, Calif., ETATS-UNIS

Résumé / Abstract

Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallel-group study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Antidepressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of ≤ 7 on the HAM-D and ≤ 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0% for sertraline, 50 mg; 46% for sertraline, 100 mg; and 31% for fluoxetine, 20 mg (p =.023). At 6 weeks, positive treatment response rates were 21%, 43%, and 31% for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40% for sertraline, 100 mg; 43% for sertraline, 200 mg; and 55% for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later.

Revue / Journal Title

The Journal of clinical psychiatry   ISSN 0160-6689 

Source / Source

Congrès
Annual meeting of the American Psychiatric Association N^o153, Chicago, Ill. , ETATS-UNIS (17/05/2000)
2000, vol. 61, n^o12, pp. 942-946 (15 ref.)

Langue / Language

Anglais

Editeur / Publisher

Physicians Postgraduate Press, Memphis, TN, ETATS-UNIS  (1978) (Revue)

Mots-clés anglais / English Keywords

Depression ; Treatment ; Chemotherapy ; Sertraline ; Comparative study ; Fluoxetine ; Reuptake inhibitor ; Serotonin ; Antidepressant agent ; Psychotropic ; Dose activity relation ; Response time ; Treatment efficiency ; Toxicity ; Follow up study ; Human ; Mood disorder ;

Mots-clés français / French Keywords

Etat dépressif ; Traitement ; Chimiothérapie ; Sertraline ; Etude comparative ; Fluoxétine ; Inhibiteur recapture ; Sérotonine ; Antidépresseur ; Psychotrope ; Relation dose réponse ; Temps réponse ; Efficacité traitement ; Toxicité ; Etude longitudinale ; Homme ; Trouble humeur ;

Mots-clés espagnols / Spanish Keywords

Estado depresivo ; Tratamiento ; Quimioterapia ; Sertralina ; Estudio comparativo ; Fluoxetina ; Inhibidor recaptura ; Serotonina ; Antidepresor ; Psicotropo ; Relación dosis respuesta ; Tiempo respuesta ; Eficacia tratamiento ; Toxicidad ; Estudio longitudinal ; Hombre ; Trastorno humor ;

Localisation / Location

INIST-CNRS, Cote INIST : 9069, 35400009394512.0090